Analysis of Prognostic Factors in Acute Leukemias in Adults

Krykowski, E; Polkowska-Kulesza, E; Robak, T; Matusewicz, W; Urbańska-Ryś, H; Hołub, Adam

doi:10.1007/978-3-642-71213-5_61

Cited by 3 publications

(4 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, the WBC counts were divided into four levels in our study (12–14): low (<20 × 10 9 /L), high (20–50 × 10 9 /L), higher (51–100 × 10 9 /L), and highest (>100 × 10 9 /L). The prognostic platelet counts consisted of three subgroups (15): normal (>100 × 10 9 /L), low (30–100 × 10 9 /L), and lower (<30 × 10 9 /L). The cytogenetic results were classified into three, such as (1–8): favorable‐risk, intermediate‐risk, and unfavorable‐risk cytogenetics.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia

et al. 2010

Apmis

View full text Add to dashboard Cite

Immunophenotyping is one of the independent prognostic factors in acute myeloid leukemia (AML). Relevance of immunophenotypes to prognostic subgroups of age, white blood cells (WBC), platelet count, and cytogenetics in de novo AML was comprehensively investigated in this study for the first time. Human leukocyte antigen (HLA)-DR and CD14 expression associated with the elderly, highest WBC count, and unfavorable-risk cytogenetics; CD4, CD7, and CD11b expression correlated with highest WBC count and unfavorable-risk cytogenetics; CD64 expression was associated with higher WBC count while that of CD13 was associated with lower platelet count; CD22, CD34, CD123, and terminal deoxynucleotidyl transferase (TdT) expression correlated with unfavorable-risk cytogenetics; CD5 expression was associated with normal platelet count while that of CD19 was associated with children and favorable-risk cytogenetics; CD117 expression was associated with low WBC and lower platelet counts; myeloperoxidase (MPO) expression correlated with lower platelet count; and MPO and glycophorin A (Gly-A) expression was associated with lower WBC count and favorable-risk cytogenetics. The results of the relevance analysis revealed the distribution characteristics of antigen expression in different AML prognostic subgroups. The majority of antigens associated with good or poor prognostic subgroups were in accordance with the previous reports of correlation of expression of these antigens with prognosis. Antigens associated with good (or poor) prognostic subgroups were defined as good (or poor)-risk antigens.

show abstract

Section: Methodsmentioning

confidence: 99%

“…Several clinical and biologic features that reflect the heterogeneity of acute myeloid leukemia (AML) are related to the treatment outcome of AML (1–17). These prognostic factors include age, white blood cell (WBC) count, platelet count, lactate dehydrogenase, multiple drug resistance, immunophenotyping, cytogenetics, molecular genetics, microRNA, and so on.…”

mentioning

confidence: 99%

Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia

et al. 2010

Apmis

View full text Add to dashboard Cite

show abstract

“…Lactate dehydrogenase (LDH) is a well-established biomarker capable of aiding prognosis in a variety of cancers including AML [ 42 , 43 , 44 , 45 ]. Recent studies have indicated the potential of LDH as a prognostic marker in AML patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT), as well as a predictive marker of AML patient outcome following sibling bone marrow transplant (BMT) [ 46 , 47 ].…”

Section: Discussionmentioning

confidence: 99%

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches

et al. 2021

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is characterized by an increasing number of clonal myeloid blast cells which are incapable of differentiating into mature leukocytes. AML risk stratification is based on genetic background, which also serves as a means to identify the optimal treatment of individual patients. However, constant refinements are needed, and the inclusion of significant measurements, based on the various omics approaches that are currently available to researchers/clinicians, have the potential to increase overall accuracy with respect to patient management. Using both nontargeted (label-free mass spectrometry) and targeted (multiplex immunoassays) proteomics, a range of proteins were found to be significantly changed in AML patients with different genetic backgrounds. The inclusion of validated proteomic biomarker panels could be an important factor in the prognostic classification of AML patients. The ability to measure both cellular and secreted analytes, at diagnosis and during the course of treatment, has advantages in identifying transforming biological mechanisms in patients, assisting important clinical management decisions.

show abstract

“…Prediction of success (or failure) of chemotherapy is important because alternative < treatments such as stem cell transplantation might be an option for some patients with refractory disease. Several prognostic factors predictive for poor response to induction therapy, such as age [11], unfavorable karyotype [12][13][14], presence of drug-resistance proteins [15][16][17][18][19][20][21], high WBC [22] and low platelet counts [23], have been described. We studied a group of patients with highly refractory AML, defined by a failure to clear blasts from the peripheral blood at the time of maximum effect of chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

Highly refractory acute myeloid leukemia

Füreder¹,

Filipits²,

Sperr³

et al. 2004

Wien Klin Wochenschr

View full text Add to dashboard Cite

In this study we evaluated 103 patients suffering from acute myeloid leukemia (AML) who did not respond to induction chemotherapy and defined a sub-group of patients with highly refractory disease characterized by a persistence of more than 1 G/L blast cells in the peripheral blood between days 12 and 16 of the first induction cycle. Only seven patients (one female, six males) met these criteria. Their median age was 65 years (range 41-82 years). Four had de novo AML and three secondary AML. Cytogenetic analysis was performed in six patients: complex aberrations were detected in four patients and, unexpectedly, normal karyotypes were found in the other two. Analysis of multidrug-resistance factors revealed high co-expression of P-glycoprotein (P-gp) and lung resistance protein (LRP) in all four patients with highly refractory disease tested a finding in only 6% of patients with refractory disease and 3% of patients who achieved complete remission (CR) of disease. Furthermore, patients with highly refractory AML had substantially higher leukocyte counts than patients with refractory AML or CR, although this was not significant statistically. Overall, patients with highly refractory AML are characterized by a high incidence of complex cytogenetic aberrations and marked expression of drug transporters.

show abstract

Analysis of Prognostic Factors in Acute Leukemias in Adults

Cited by 3 publications

References 7 publications

Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia

Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia

Identification of Protein Biomarker Signatures for Acute Myeloid Leukemia (AML) Using Both Nontargeted and Targeted Approaches

Highly refractory acute myeloid leukemia

Contact Info

Product

Resources

About